Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraprostatic Botulinum Toxin A for Symptomatic BPH
NCT01275521Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jan 2011
- Primary completion
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of botulinum toxin type A in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: International Prostate Symptom Score at 4 months. Started Jan 2011; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT01275521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01275521.